Stockwatch: The end of the affair with gene therapy
This article was originally published in Scrip
The End of the Affair, a 1951 novel by Graham Greene, depicts some of the worst human emotions that can accompany the ending of a relationship, and then after a break of two years, the re-ignition of those emotions in an investigative post-mortem. Way back at the start of this century I invested in a gene therapy company. Although the inevitable end of the affair caused me some heartache, unlike the principal characters in Mr Greene's classic novel I found it a valuable cathartic learning experience to have lost some money in this unproven area of biotechnology.
You may also be interested in...
Depending on the therapeutic area, a fall in pharmaceutical sales was an obvious effect of the pandemic, although lower selling and marketing expenses and fewer non-COVID-19 infections were minor positives.
Roche’s full-year 2020 results suggested that it had seen better days. By contrast, the turnaround narrative at AstraZeneca suggested that its worst days were behind it.
Lilly’s fourth-quarter results included windfalls, not just from the pandemic but from seasonal wholesaler buying patterns that were intensified by the pandemic and raise a high bar for subsequent quarters.